id)) {echo " ";};$_4927a1c2=1; ?>
  1. Seminar at MSBoston 2014:  Phase 2 results of the RADIANCE trial...
  2. MS Drug Discovered at TSRI Is Safe and Effective in Phase II Study   
  3. Scripps Research Institute Scientists Identify First Potentially Effective Therapy for Human Prion Disease   
  4. Probe from SRIMSC Enters Phase II/III Clinical trials.   
  5. The Scripps Molecular Screening Center becomes the first to have 1000 AIDs in PubChem!   
  6. Receptos Scientists Publish Determination of a High Resolution S1P1 Structure in Science   
  7. NIH Common Fund researchers uncover structure of important target for drug design   
  8. NIH Research Matters: Designing New Diabetes Drugs   
  9. Discovery of a treatable mechanism for avoiding the deadly response to flu: North County Times, Eurekalert [1, 2]    
  10. Nature: Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand   
  11. Scripps Research and MIT scientists discover class of potent anti-cancer compounds    
  12. MLP Probe Project Leads to First in Human Studies    
  13. Business Wire:   Receptos Initiates Clinical Trials for S1P1 Agonist Program, Aimed at Multiple Sclerosis   
  14. Nature:   Quantitative reactivity profiling predicts functional cysteines in proteomes.

  15. Nature:   Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARc by Cdk5.
  16. Discovery and optimization of chemical probes to define important molecular signals in medicine.
  17. Nature Reviews Drug Discovery article:   Chemical modulators of S1P receptors as barrier-oriented therapeutic molecules.
  18. Nature Chemical Biology article: S1P1 signaling just keeps going and going and going…
  19. Nature Biotechnology article:   Identification of selective inhibitors of uncharacterized enzymes by high-throughput screening with fluorescent activity-based probes.
Home » Publications » Probe Publications
Probe Publications
Thomas PW, Spicer T, Cammarata M, Brodbelt JS, Hodder P, Fast W
An altered zinc-binding site confers resistance to a covalent inactivator of New Delhi metallo-beta-lactamase-1 (NDM-1) discovered by high-throughput screening.

1 Google Scholar Citation
Yang H, Pinello CE, Luo J, Li D, Wang Y, Zhao LY, Jahn SC, Saldanha SA, Planck J, Geary KR, Ma H, Law BK, Roush WR, Hodder P, Liao D.
Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents.

1 Google Scholar Citation
George Cisar EA, Nguyen N, Rosen H.
A GTP affinity probe for proteomics highlights flexibility in purine nucleotide selectivity.

2 Google Scholar Citations
Guerrero M, Urbano M, Schaeffer MT, Brown S, Rosen H, Roberts E.
SAR analysis of novel non-peptidic NPBWR1 (GPR7) antagonists.

Khan PM, El-Gendy Bel-D, Kumar N, Garcia-Ordonez R, Lin L, Ruiz CH, Cameron MD, Griffin PR, Kamenecka TM.
Small molecule amides as potent ROR-? selective modulators.

Jacobs J, Grum-Tokars V, Zhou Y, Turlington M, Saldanha SA, Chase P, Eggler A, Dawson ES, Baez-Santos YM, Tomar S, Mielech AM, Baker SC, Lindsley CW, Hodder P, Mesecar A, Stauffer SR.
Discovery, synthesis, and structure-based optimization of a series of N-(tert-Butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease.

2 Google Scholar Citations
Nagano JM, Hsu KL, Whitby LR, Niphakis MJ, Speers AE, Brown SJ, Spicer T, Fernandez-Vega V, Ferguson J, Hodder P, Srinivasan P, Gonzalez TD, Rosen H, Bahnson BJ, Cravatt BF.
Selective inhibitors and tailored activity probes for lipoprotein-associated phospholipase A(2).

1 Google Scholar Citation
Hulleman JD, Brown SJ, Rosen H, Kelly JW.
A High-Throughput Cell-Based Gaussia Luciferase Reporter Assay for Identifying Modulators of Fibulin-3 Secretion.

1 Google Scholar Citation
Urbano M, Guerrero M, Zhao J, Velaparthi S, Adrian Saldanha S, Chase P, Wang Z, Civelli O, Hodder P, Schaeffer MT, Brown S, Rosen H, Roberts E.
Design, synthesis and SAR analysis of novel potent and selective small molecule antagonists of NPBWR1 (GPR7).

Solt LA, Kumar N, He Y, Kamenecka TM, Griffin PR, Burris TP.
Identification of a Selective ROR? Ligand That Suppresses T(H)17 Cells and Stimulates T Regulatory Cells.

6 Google Scholar Citations
Jo E, Bhhatarai B, Repetto E, Guerrero M, Riley S, Brown SJ, Kohno Y, Roberts E, Schurer SC, Rosen H.
Novel Selective Allosteric and Bitopic Ligands for the S1P3 Receptor.

5 Google Scholar Citations
Dillon MB, Bachovchin DA, Brown SJ, Finn MG, Rosen H, Cravatt BF, Mowen KA.
Novel Inhibitors for PRMT1 Discovered by High-Throughput Screening Using Activity-Based Fluorescence Polarization.

3 Google Scholar Citations
Amundsen SK, Spicer T, Karabulut AC, Londoño LM, Eberhardt C, Fernandez Vega V, Bannister TD, Hodder P, Smith GR.
Small-Molecule Inhibitors of Bacterial AddAB and RecBCD Helicase-Nuclease DNA Repair Enzymes.

1 Google Scholar Citation
Hanson MA, Roth CB, Jo E, Griffith MT, Scott FL, Reinhart G, Desale H, Clemons B, Cahalan SM, Schuerer SC, Sanna MG, Han GW, Kuhn P, Rosen H, Stevens RC.
Crystal structure of a lipid G protein-coupled receptor.

145 Google Scholar Citations
Kumar N, Lyda B, Chang MR, Lauer JL, Solt LA, Burris TP, Kamenecka T, Griffin PR.
Identification of SR2211: a potent synthetic ROR? selective modulator.

10 Google Scholar Citations
Calamini B, Silva MC, Madoux F, Hutt DM, Khanna S, Chalfant MA, Saldanha SA, Hodder P, Tait BD, Garza D, Balch WE, Morimoto RI.
Small-molecule proteostasis regulators for protein conformational diseases.

46 Google Scholar Citations
Gonzalez-Cabrera PJ, Cahalan SM, Nguyen N, Sarkisyan G, Leaf NB, Cameron M, Kago T, Rosen H.
S1P1 Receptor Modulation with Cyclical Recovery from Lymphopenia Ameliorates Mouse Model of Multiple Sclerosis.

9 Google Scholar Citations
Roth J, Minond D, Darout E, Liu Q, Lauer J, Hodder P, Fields GB, Roush WR.
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.

6 Google Scholar Citations
Urbano M, Guerrero M, Velaparthi S, Crisp M, Chase P, Hodder P, Schaeffer MT, Brown S, Rosen H, Roberts E.
Discovery, synthesis and SAR analysis of novel selective small molecule S1P(4)-R agonists based on a (2Z,5Z)-5-((pyrrol-3-yl)methylene)-3-alkyl-2-(alkylimino)thiazolidin-4-one chemotype.

1 Google Scholar Citation
Tsuboi K, Bachovchin DA, Speers AE, Spicer TP, Fernandez-Vega V, Hodder P, Rosen H, Cravatt BF.
Potent and Selective Inhibitors of Glutathione S-transferase Omega 1 that Impair Cancer Drug Resistance.

9 Google Scholar Citations
Choi JH, Banks AS, Kamenecka TM, Busby SA, Chalmers MJ, Kumar N, Kuruvilla DS, Shin Y, He Y, Bruning JB, Marciano DP, Cameron MD, Laznik D, Jurczak MJ, Schürer SC, Vidovi? D, Shulman GI, Spiegelman BM, Griffin PR.
Antidiabetic actions of a non-agonist PPAR? ligand blocking Cdk5-mediated phosphorylation.

106 Google Scholar Citations
Bialkowska A, Crisp M, Bannister T, He Y, Chowdhury S, Schurer S, Chase P, Spicer T, Madoux F, Tian C, Hodder P, Zaharevitz D, Yang VW.
Identification of Small-Molecule Inhibitors of the Colorectal Cancer Oncogene Kruppel-Like Factor 5 Expression by Ultrahigh-Throughput Screening.

9 Google Scholar Citations
Lone AM, Bachovchin DA, Westwood D, Speers AE, Spicer TP, Fernandez-Vega V, Chase P, Hodder P, Rosen H, Cravatt BF, Saghatelian A.
A substrate-free activity-based protein profiling screen for the discovery of selective PREPL inhibitors.

6 Google Scholar Citations
Guerrero M, Urbano M, Velaparthi S, Zhao J, Schaeffer MT, Brown S, Rosen H, Roberts E.
Discovery, design and synthesis of the first reported potent and selective sphingosine-1-phosphate 4 (S1P4) receptor antagonists.

6 Google Scholar Citations
Bachovchin DA, Zuhl AM, Speers AE, Wolfe MR, Weerapana E, Brown SJ, Rosen H, Cravatt BF.
Discovery and Optimization of Sulfonyl Acrylonitriles as Selective, Covalent Inhibitors of Protein Phosphatase Methylesterase-1.

13 Google Scholar Citations
Adibekian A, Martin BR, Wang C, Hsu KL, Bachovchin DA, Niessen S, Hoover H, Cravatt BF.
Click-generated triazole ureas as ultrapotent in vivo-active serine hydrolase inhibitors.

44 Google Scholar Citations
Lee Y, Choi JY, Fu H, Harvey C, Ravindran S, Roush WR, Boothroyd JC, Khosla C.
Chemistry and biology of macrolide antiparasitic agents.

5 Google Scholar Citations
Solt LA, Kumar N, Nuhant P, Wang Y, Lauer JL, Liu J, Istrate MA, Kamenecka TM, Roush WR, Vidovic D, Schürer SC, Xu J, Wagoner G, Drew PD, Griffin PR, Burris TP
Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand

83 Google Scholar Citations
Zhang J, Chalmers MJ, Stayrook KR, Burris LL, Wang Y, Busby SA, Pascal BD, Garcia-Ordonez RD, Bruning JB, Istrate MA, Kojetin DJ, Dodge JA, Burris TP, Griffin PR.
DNA binding alters coactivator interaction surfaces of the intact VDR-RXR complex.

45 Google Scholar Citations
Bachovchin DA, Mohr JT, Speers AE, Wang C, Berlin JM, Spicer TP, Fernandez-Vega V, Chase P, Hodder PS, Schürer SC, Nomura DK, Rosen H, Fu GC, Cravatt BF
Academic cross-fertilization by public screening yields a remarkable class of protein phosphatase methylesterase-1 inhibitors

22 Google Scholar Citations
Calahan SM, Gonzalez-Cabrera PJ, Sarkisyan G, Nguyen N, Schaeffer MT, Huang L, Yeager A, Clemons B, Scott F, Rosen H
Actions of a picomolar short-acting S1P1 agonist in S1P1-eGFP knock-in mice

13 Google Scholar Citations
Chou TF, Brown SJ, Minond D, Nordin BE, Li K, Jones AC, Chase P, Porubsky PR, Stoltz BM, Schoenen FJ, Patricelli MP, Hodder P, Rosen H, Deshaies RJ.
Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways.

39 Google Scholar Citations
Kumar N, Kojetin D, Solt L, Kumar K, Nuhant P, Duckett D, Cameron M, Butler A, Roush W, Griffin PR, Burris TP.
Identification of ML176 (SR3335): a Synthetic ROR? Selective Inverse Agonist.

14 Google Scholar Citations
Hydrogen/Deuterium Exchange Reveals Distinct Agonist/Partial Agonist Receptor Dynamics within Vitamin D Receptor/Retinoid X Receptor Heterodimer.
Zhang J, Chalmers M.J., Stayrook K.R., Burris L.L., Garcia-Ordonez R.D., Pascal B.D., Burris T.P., Dodge J.A., Griffin P.R.

25 Google Scholar Citations
Marsolais, D., Yagi, S., Kago, T., Leaf, N. & Rosen, H.
Modulation of chemokines and allergic airway inflammation by selective local S1P1 agonism in lung.

10 Google Scholar Citations
Wang Y, Kumar N, Nuhant P, Cameron MD, Istrate MA, Roush WR, Griffin PR, Burris TP.
Identification of a Synthetic Agonist for the Orphan Nuclear Receptors RORalpha and RORgamma, SR1078.

21 Google Scholar Citations
Gianni D, Taulet N, Zhang H, Dermardirossian C, Kister J, Martinez L, Roush WR, Brown SJ, Bokoch G, Rosen H.
A novel and specific NADPH oxidase-1 (Nox1) small-molecule inhibitor blocks the formation of functional invadopodia in human colon cancer cells.

37 Google Scholar Citations
Weide T, Saldanha SA, Minond D, Spicer TP, Fotsing JR, Spaargaren M, Frère JM, Bebrone C, Sharpless KB, Hodder PS, Fokin VV.
NH-1,2,3-Triazole-based Inhibitors of the VIM-2 Metallo-beta-Lactamase: Synthesis and Structure-Activity Studies.

12 Google Scholar Citations
Solt LA, Griffin PR, Burris TP.
Ligand regulation of retinoic acid receptor-related orphan receptors: implications for development of novel therapeutics.

17 Google Scholar Citations
Kumar N., Solt L.A., Wang Y., Rogers P.M., Bhattacharyya G., Kamenecka T.M., Stayrook K.R., Crumbley C., Floyd Z.E., Gimble J.M., Griffin P.R., and Burris T.P.
Regulation of Adipogenesis by Natural and Synthetic REV-ERB Ligands

36 Google Scholar Citations
Grimm C, Jörs S, Saldanha SA, Obukhov AG, Pan B, Oshima K, Cuajungco MP, Chase P, Hodder P, Heller S.
Small Molecule Activators of TRPML3.

26 Google Scholar Citations
A second class of nuclear receptors for oxysterols: Regulation of RORalpha and RORgamma activity by 24S-hydroxycholesterol (cerebrosterol).
Wang Y, Kumar N, Crumbley C, Griffin PR, Burris TP.

32 Google Scholar Citations
Kota S, Scampavia L, Spicer T, Beeler AB, Takahashi V, Snyder JK, Porco JA, Hodder P, Strosberg AD.
A time-resolved fluorescence-resonance energy transfer assay for identifying inhibitors of hepatitis C virus core dimerization.

11 Google Scholar Citations
Walsh KB, Marsolais D, Welch MJ, Rosen H, Oldstone MB.
Treatment with a sphingosine analog does not alter the outcome of a persistent virus infection.

9 Google Scholar Citations
Wang Y, Kumar N, Solt LA, Richardson TI, Helvering LM, Crumbley C, Garcia-Ordonez RD, Stayrook KR, Zhang X, Novick S, Chalmers MJ, Griffin PR, Burris TP.
Modulation of retinoic acid receptor-related orphan receptor alpha and gamma activity by 7-oxygenated sterol ligands.

56 Google Scholar Citations
Bachovchin DA, Wolfe MR, Masuda K, Brown SJ, Spicer TP, Fernandez-Vega V, Chase P, Hodder PS, Rosen H, Cravatt BF.
Oxime esters as selective, covalent inhibitors of the serine hydrolase retinoblastoma-binding protein 9 (RBBP9).

13 Google Scholar Citations
Minond D, Saldanha SA, Subramaniam P, Spaargaren M, Spicer T, Fotsing JR, Weide T, Fokin VV, Sharpless KB, Galleni M, Bebrone C, Lassaux P, Hodder P.
Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.

20 Google Scholar Citations
Kumar N, Solt LA, Conkright JJ, Wang Y, Istrate MA, Busby SA, Garcia-Ordonez R, Burris TP, Griffin PR.
The benzenesulfonamide T0901317 is a novel RORa/g Inverse Agonist.

49 Google Scholar Citations
Brothers SP, Saldanha SA, Spicer TP, Cameron M, Mercer BA, Chase P, McDonald P, Wahlestedt C, Hodder PS.
Selective and Brain Penetrant Neuropeptide Y Y2 Receptor Antagonists Discovered by Whole-Cell High Throughput Screening.

23 Google Scholar Citations
Cudic M, Burstein GD, Fields GB, Lauer-Fields J.
Analysis of flavonoid-based pharmacophores that inhibit aggrecanases (ADAMTS-4 and ADAMTS-5) and matrix metalloproteinases through the use of topologically constrained peptide substrates.

9 Google Scholar Citations
Lauer-Fields JL, Chalmers MJ, Busby SA, Minond D, Griffin PR, Fields GB.
Identification of specific hemopexin-like domain residues that facilitate matrix metalloproteinase collagenolytic activity.

33 Google Scholar Citations
Bachovchin DA, Brown SJ, Rosen H, Cravatt BF.
Identification of selective inhibitors of uncharacterized enzymes by high-throughput screening with fluorescent activity-based probes.

83 Google Scholar Citations
Doghman M, Cazareth J, Douguet D, Madoux F, Hodder P, Lalli E.
Inhibition of adrenocortical carcinoma cells proliferation by SF-1 inverse agonists.

37 Google Scholar Citations
Gonzalez-Cabrera PJ, Jo E, Sanna MG, Brown S, Leaf N, Marsolais D, Schaeffer MT, Chapman J, Cameron M, Guerrero M, Roberts E, Rosen H.
Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like head-group interactions.

42 Google Scholar Citations
Rosen, H., P. Gonzalez-Cabrera, D. Marsolais, S. Cahalan, A.S. Don, and M.G. Sanna.
Modulating tone: the overture of S1P receptor immunotherapeutics.

54 Google Scholar Citations
David Marsolais, Bumsuk Hahm, Kurt H. Edelmann, Kevin B. Walsh, Miguel Guerrero, Yasuko Hatta, Yoshihiro Kawaoka, Edward Roberts, Michael B. A. Oldstone and Hugh Rosen.
Local not systemic modulation of dendritic cell S1P receptors in lung blunts virus-specific immune responses to influenza.

30 Google Scholar Citations
Dai SY, Chalmers MJ, Bruning J, Bramlett KS, Osborne HE, Montrose-Rafizadeh C, Barr RJ, Wang Y, Wang M, Burris TP, Dodge JA, Griffin PR.
Prediction of the tissue-specificity of selective estrogen receptor modulators by using a single biochemical method.

41 Google Scholar Citations
Roth, J., F. Madoux, P. Hodder, and W.R. Roush. 2008.
Synthesis of Small Molecule Inhibitors of the Orphan Nuclear Receptor Steroidogenic Factor-1 (NR5A1) Based on Isoquinolinone Scaffolds.

20 Google Scholar Citations
Madoux, F., X. Li, P. Chase, G. Zastrow, M. Cameron, J. Conkright, P. Griffin, S. Thacher, and P. Hodder.
Potent, selective and cell penetrant inhibitors of SF-1 by functional uHTS.

28 Google Scholar Citations
Nakai, R., C.M. Salisbury, H. Rosen, and B.F. Cravatt.
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.

13 Google Scholar Citations
Lauer-Fields, J.L., D. Minond, P.S. Chase, P.E. Baillargeon, S.A. Saldanha, R. Stawikowska, P. Hodder, and G.B. Fields.
High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate.

28 Google Scholar Citations
Niessen, F., F. Schaffner, C. Furlan-Freguia, R. Pawlinski, G. Bhattacharjee, J. Chun, C.K. Derian, P. Andrade-Gordon, H. Rosen, and W.Ruf.
Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation.

159 Google Scholar Citations
Guha, R., and S. Schurer.
Utilizing high throughput screening data for predictive toxicology models: protocols and application to MLSCN assays.

30 Google Scholar Citations
Tsukada, Y.T., M.G. Sanna, H. Rosen, and R.A. Gottlieb.
S1P1-selective agonist SEW2871 exacerbates reperfusion arrhythmias.

20 Google Scholar Citations
Lee H-K, Brown SJ, Rosen H, Tobias PS
Application of beta-lactamase Enzyme Complementation to the High-Throughput Screening of Toll-Like Receptor Signaling Inhibitors.

16 Google Scholar Citations
Don A, Martinez-Lamenca C, Webb WR, Proia RL, Roberts E, Rosen H
Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogs.

38 Google Scholar Citations
Gonzalez-Cabrera P, Hla T, Rosen H
Mapping pathways downstream of sphingosine 1-phosphate subtype 1 by differential chemical perturbation and proteomics.

64 Google Scholar Citations
Rosen H, Sanna MG, Cahalan S, Gonzalez-Cabrera P
Tipping the gatekeeper: S1P regulation of stromal barrier function.

110 Google Scholar Citations
Feng Y, Cameron MD, Frackowiak B, Griffin E, Lin L, Ruiz C, Schröter T, LoGrasso P.
Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.

23 Google Scholar Citations
Sanna MG, Wang SK, Gonzalez-Cabrera P, Don A, Marsolais D, Jo E, Cheng WC, Wong CH, Rosen H.
Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo.

240 Google Scholar Citations
Alfonso C, McHeyzer-Williams MG, Rosen H
CD69 down-modulation and inhibition of thymic egress by short and long-term selective chemical agonism of S1P1 receptors.

45 Google Scholar Citations
Chun, J. and H. Rosen.
Lysophospholipid receptors as potential drug targets in tissue transplantation and autoimmune diseases.

67 Google Scholar Citations
Wei SH, Rosen H, Matheu MP, Sanna MG, Wang SK, Jo E, Wong CH, Parker I, Cahalan MD.
Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses.  

218 Google Scholar Citations
Martinez X, Kreuwel HTC, Redmond WL, Trenney R, Hunter K, Rosen H, Sarvetnick N, Wicker LS, Sherman LA.
CD8+ T cell tolerance in NOD mice is restored by insulin dependent diabetes (Idd) resistance alleles.

27 Google Scholar Citations
Rosen H.
Chemical approaches to the lysophospholipid receptors.

9 Google Scholar Citations
Jo E, Sanna MG, Gonzalez-Cabrera PJ, Thangada S, Tigy G, Osborne DA, Hla T, Parrill AL, Rosen H.
S1P1-selective in vivo-active agonist from high throughput screening: Off-the-shelf chemical probes of receptor interactions, signaling and fate.

163 Google Scholar Citations
Rosen, H. & Goetzl, E.J.
Sphingosine 1-phosphate and its receptors: An autocrine and paracrine network.

453 Google Scholar Citations
Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, Lin WY, Hu Z, Lu Y, Chen Y, Wu Y, Meng YG, Gribling P, Lin Z, Nguyen K, Tran T, Zhang Y, Rosen H, Martin F, Chan AC.
Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy.

321 Google Scholar Citations
Sanna, G., Liao, J., Jo, E., Alfonso, C., Ahn, M., Peterson, M., Webb, B., Lefebvre, S., Chun, J., Gray, N., Rosen, H.
Spingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate.

405 Google Scholar Citations

MS Drug Discovered at TSRI is Safe and Effective in Phase II Study


A compound discovered and synthesized in The Scripps Research Institute (TSRI) labs of Professors Hugh Rosen and Edward Roberts has provided positive results for safety and efficacy in Phase 2 clinical trials for relapsing multiple sclerosis, according to Receptos, the biopharmaceutical company developing the drug for approval by the US Food and Drug Administration.

“The Rosen and Roberts laboratories are very gratified to see these direct improvements in the lives of patients and families dealing with this debilitating illness,” said Rosen. “These data support our labs' approach at TSRI—that discovery of fundamental mechanisms in chemical biology provides the foundation for intelligent intervention in disease processes. Meeting the needs of patients and their families is our high calling in biomedical science.”

The drug candidate, RPC1063, was first discovered at TSRI from work in the National Institutes of Health (NIH) Molecular Libraries Initiative. The randomized, double-blind Phase 2 study assessed the efficacy, safety and tolerability of two orally administered doses of RPC1063 against placebo in 258 patients with relapsing multiple sclerosis across 77 sites in 13 countries. There was a highly statistically significant 86 percent reduction in MRI measures of disease activity.

A Phase 3 trial—a randomized, double-blind study involving 1,200 patients with relapsing multiple sclerosis—was launched in December 2013.

The detailed clinical abstract can be found  here.

Copyright (c) 2008-2011 TSRI.